Global Stem Cell Therapy Market Future Outlook

Stem cells are specialized cells that can differentiate into other cells without losing their
identity. They have been found to be present in animals as well as humans and most of the
work has been done on mice. Investigators have found that stem cells are part of repair
system and helps in maintaining the normal bodily functions. They divide to give rise to
two cells out of which one remains the same while other differentiates into the required
cell type. They can replenish throughout the life-time and they could repair damaged
organs in order to prevent further damage. They are also influenced by external cues due
to which they could be converted into different cell type. It is expected that investigators
would be able to make new discoveries that would allow them to assign new properties to
stem cells. More research is required in this segment to fully understand the properties of
stem cells.
Investigators are trying to decipher stem cells biochemical and biophysical properties so
that they could develop them as a therapeutic commodity. Their ability to convert into
different cell types could be used for developing regenerative medicines. Organ
regeneration at laboratory levels have been achieved but it will take some time for
developing fully functional transplantable organ. Investigators have found they could be
used for various oncological applications. Modified stem cells could be used for curing
cancer and some success has been achieved in past years. Their utility in cardiovascular
diseases has been noted as they have ability to regenerate damaged cardiac muscles. In
neural disorders like Alzheimer's disease and Parkinson's disease their role is being studied
as presently available therapeutics have modest efficacy with short-lived effects.
Innovations in pharmaceutical industry seem to be the main driving force for the
development of stem cell therapies. Investigators have been able to identify different
stem cell sources which offers them large base for developing new therapies. Their
customizability and appropriate usage is expected to help them to discover new
pharmacological properties that may have high commercialization potential. As a result,
large numbers of stem cell therapies are entering in clinical trials across the globe. They
are at different stages of development and likely to be introduced in global market in
coming years. This will help the stem cell therapy developers to generate significant
revenues in coming years. However, this scenario may take few years to materialize but
some stem cell therapies have already entered in market which are in clinical practice for
past years.

As per recent research report "Global Stem Cell Therapy Market Future Outlook " published
by KuicK Research, advancement in stem cell research seems to be increasing continuously
across the globe which is apparent from the number of increasing clinical trials. Stem cell
therapies for numerous indications are at different stages of clinical trials and they would
be introduced in market in coming years. Increased findings and quest for better
therapeutics could be considered as main reason behind growth of this segment. Improved
technology and development of innovative modalities are further expected to propel the
development of stem cell therapies. Only few stem cell therapies have received approval
and most of them are small part of forth coming medical revolution. Stem cell therapy
developers would be able to generate significant revenues in coming years. In this way,
future prospects of stem cell therapies look optimistic and it is expected that more stem
cell therapies would be commercialized in coming years.
"Global Stem Cell Therapy Market Future Outlook" Report Highlight:

Global Stem Cell Market Analysis

Trends in Stem Cell Research

Global Stem Cell Market Dynamics: Favorable Factors & Commercialization

Challenges

Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase

Global Stem Cell Therapies in Clinical Pipeline: 114 Therapies

Majority Stem Cell Therapies in Preclinical Phase: 38 Therapies

Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company &
Indication

Marketed Stem Cell Therapies Clinical: 2 Therapies (Adipocell & VesCell)

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents
1. Introduction to Stem Cells
2. Classification of Stem Cells
2.1 Basis of Ability to Differentiate
2.2 Basis of Origin
2.3 Basis of their Source
3. Different Type of Stem Cell Transplants
3.1 Autologous Stem Cell Transplants
3.2 Allogeneic Stem Cell Transplants
3.3 Syngeneic Stem Cell Transplants
4. Mechanism of Stem Cell Therapy
5. Trends in Stem Cell Research
5.1 Stem Cell Therapy for Cardiovascular Diseases
5.2 Stem Cell Therapy for Cancer Treatment
5.3 Stem Cell Therapy for Central Nervous System Disorders
5.4 Stem Cell Therapy for Ophthalmic Disorders
5.5 Stem Cell Therapy for Metabolic Disorders
5.6 Stem Cell Therapy for Gastrointestinal Diseases
6. Global Stem Cell Market Analysis
6.1 Current Market Scenario
6.2 Global Stem Cell Therapies Pipeline Overview
7. Global Stem Cell Market Dynamics
7.1 Favorable Factors
7.2 Commercialization Challenges

8. Stem Cell Market Future Prospects

9. Global Stem Cell Therapies Clinical Pipeline by Company, Indication &
Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-III
9.8 Registered
10. Marketed Stem Cell Therapies Clinical Insight by Brand Name,
Company & Indication
10.1 Adipose Stem Cell Therapy (Adipocell)
10.2 Angiogenic Cell Precursor Therapy (VesCell)
11. Discontinued & Suspended Stem Cell Therapies in Clinical Pipeline
11.1 No Development Reported
11.2 Discontinued
11.3 Suspended
12. Competitive Landscape
12.1 Aldagen
12.2 AlloCure
12.3 Anterogen
12.4 Arteriocyte Medical Systems
12.5 Athersys Inc.
12.6 Baxter Healthcare Corporation
12.7 Bioheart

12.8 Cambridge Enterprise Ltd

12.9 Celyad
12.10 Celgene Corporation
12.11 Cellerant Therapeutics
12.12 Cellonis Biotechnologies
12.13 CellPraxis
12.14 Chiesi
12.15 Caladrius
12.16 Cryopraxis
12.17 Cytori Therapeutics
12.18 Gamida Cell
12.19 Genexine
12.20 Geron
12.21 Intrexon Corporation
12.22 K-STEMCELL
12.23 Lifecells LLC
12.24 Medipost
12.25 Medistem Panama
12.26 Mesoblast
12.27 Novartis
12.28 Nuo Therapeutics
12.29 Ocata Therapeutics
12.30 OmniCyte Ltd
12.31 OncoMed
12.32 Osiris Therapeutics
12.33 Pharmicell

12.34 Pluristem Therapeutics

12.35 Promethera Biosciences
12.36 ReNeuron
12.37 Stem Cell Sciences (SCS)
12.38 Stem Cells
12.39 Stemedica Cell Technologies
12.40 TCA Cellular Therapy
12.41 TheraVitae
12.42 TiGenix
12.43 Vericel Corporation

List of Figures
Figure 1-1: Properties of Stem Cells
Figure 1-2: Utility of Stem Cells
Figure 1-3: Benefits of Stem Cells
Figure 1-4: Limitations of Stem Cells
Figure 2-1: Type of Stem Cells on the Basis of Ability to Differentiate
Figure 2-2: Type of Stem Cells on the Basis of Origin
Figure 2-3: Types of Stem Cells on the Basis of their Source
Figure 2-4: Different Sources of Autologous Stem Cell
Figure 3-1: Different Stem Cell Transplants
Figure 4-1: Source of Hematopoietic Stem Cells
Figure 4-2: Mechanism of Stem Cells Blood Related Diseases
Figure 4-3: Mechanism of Skin treatment by Stem

Cells

Figure 4-4: Mechanism of Stem Cell Diabetes Treatment

Figure 5-1: Relevant Type of Stem Cells for CVS

Figure 5-2: Proposed Mechanism of Stem Cell Activity
Figure 6-1: Difference between Autologous & Autogenic HSCTs
Figure 6-2: Global Stem Cell Market Opportunity (US$ Billion), 2015-2020
Figure 6-3: Global Stem Cell Therapies Clinical Pipeline by Phase (%), 2015
Figure 6-4: Global Stem Cell Therapies Clinical Pipeline by Phase (Number),
2015
Figure 6-5: No Development Reported Global Stem Cell Therapies Clinical
Pipeline by Phase (%), 2015
Figure 6-6: No Development Reported Global Stem Cell Therapies Clinical
Pipeline by Phase (%), 2015
Figure 6-7: Discontinued Global Stem Cell Therapies Clinical Pipeline by Phase
(%), 2015
Figure 6-8: Discontinued Global Stem Cell Therapies Clinical Pipeline by Phase
(Number), 2015
Figure 7-1: Global Stem Cell Market Favorable Parameters
Figure 7-2: Global Stem Cell Market Commercialization Challenges
Figure 12-1: Anterogen - Clinical Pipeline
Figure 12-2: Arteriocyte Medical Systems Clinical Pipeline
Figure 12-3: Bioheart-Clinical Pipeline
Figure 12-4: Celgene-Clinical Pipeline
Figure 12-5: Cellerant-Therapeutics Clinical Pipeline
Figure 12-6: Caladrius-Clinical Pipeline
Figure 12-7: Gamida Cell- Clinical Pipeline
Figure 12-8: Genexie-Clinical Pipeline
Figure 12-9: Mesoblast Clinical Pipeline
Figure 12-10:OncoMed-Clinical Pipeline
Figure 12-11: Osiris Therapeutics- Clinical Pipeline

Figure 12-12: Pharmicell-Clinical Pipeline

Figure 12-13: Promethera- Clinical Pipeline
Figure 12-14: ReNeuron-Clinical Pipeline
Figure 12-15: Stem Cell-Clinical Pipeline
Figure 12-16: Vericel Clinical Pipeline

List of Tables

Table 2-1: Difference between Embryonic, Adult & Induced Stem Cells
Table 3-1: Comparison between Different Types of Stem Cell Transplants
Table 3-2: Few Autologous Stem Cell Therapies under Development
Table 4-1: Different Stem Cells used for Skin Treatment

For Report Sample Contact: neeraj@kuickresearch.com